.jpg?format=webp&width=780)
The article discusses the impact of highly effective modulator therapy (HEMT) on the treatment of cystic fibrosis (CF) and its influence on the timing of referral and consideration of listing for lung transplantation. While HEMT has shown significant improvement in the clinical outcomes and quality of life for people with CF, lung transplantation remains an important treatment for those with advanced disease. The article emphasizes the role of CF clinicians in ensuring timely consideration of lung transplantation in patients with advanced disease. The availability of elexacaftor/tezacaftor/ivacaftor has resulted in a drop in the number of people referred for lung transplantation, but the true impact is difficult to determine due to the COVID-19 pandemic.
Like
Save
Share